Literature DB >> 6800960

C3a-induced lysosomal enzyme secretion from human neutrophils: lack of inhibition by f met-leu-phe antagonists and inhibition by arachidonic acid antagonists.

H J Showell, M M Glovsky, P A Ward.   

Abstract

C3a-induced lysosomal enzyme secretion from human peripheral neutrophils in a noncytolytic, dose-dependent (10-100 microgram/ml) process. Release of both primary and secondary granule constituents occurred when neutrophils were exposed to C3a plus cytochalasin B, however, C3 alone induced limited release of lysozyme. A competitive antagonist of the formyl-peptide receptor on neutrophils, t boc (phe-leu) 2-phe, did not block the release induced by C3a. Arachidonic acid antagonists, nordihydroguaiaretic acid and quercetin caused dose-dependent inhibition of release induced by C3a plus cytochalasin B, however, lysozyme release induced by C3a in the absence of cytochalasin B was minimally affected. Indomethacin at high concentration (greater than 10(-5) M) had similar inhibitory effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800960     DOI: 10.1159/000233023

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  8 in total

1.  Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.

Authors:  T Kajita; T E Hugli
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

2.  Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.

Authors:  M Kings; U E Nydegger; A L de Weck
Journal:  Immunology       Date:  1984-01       Impact factor: 7.397

3.  Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a.

Authors:  S C Bischoff; A L de Weck; C A Dahinden
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  In vivo effects of C3a on neutrophils and its contribution to inflammatory lung processes in a guinea-pig model.

Authors:  T Hoffmann; E C Böttger; H P Baum; M Messner; U Hadding; D Bitter-Suermann
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

5.  Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages.

Authors:  Y Murakami; T Imamichi; S Nagasawa
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

6.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

7.  Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro.

Authors:  Z Marom; J Shelhamer; M Berger; M Frank; M Kaliner
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

Review 8.  Complement mediators: key regulators of airway tissue remodeling in asthma.

Authors:  Mohammad Afzal Khan; Abdullah Mohammed Assiri; Dieter Clemens Broering
Journal:  J Transl Med       Date:  2015-08-20       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.